{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:35:22Z","timestamp":1793435722212,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cct.2026.108452","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:36:28Z","timestamp":1788190588000},"page":"108452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Interpreting the totality of clinical study data: is there a better way? Statistical methodology for quantitatively interpreting clinical study data across efficacy endpoints"],"prefix":"10.1016","volume":"170","author":[{"given":"Diana S.","family":"Meske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Dworkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Gudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kip","family":"Vought","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Horine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Lissin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2026.108452_bb0005","series-title":"Multiple Endpoints in Clinical Trials: Guidance for Industry","author":"US Department of Health and Human Services and Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.cct.2026.108452_bb0010","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1097\/j.pain.0000000000001952","article-title":"Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations","author":"Smith","year":"2020","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.cct.2026.108452_bb0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J. Pain"},{"key":"10.1016\/j.cct.2026.108452_bb0020","article-title":"Minimal important change and difference in health outcome: an overview of approaches, concepts, and methods","author":"Dekker","year":"2023","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.cct.2026.108452_bb0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.cct.2026.108452_bb0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.cct.2026.108452_bb0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/cts.12617","article-title":"Characteristics of single pivotal trials supporting regulatory approvals of novel non-orphan, non-oncology drugs in the European Union and United States from 2012\u20132016","author":"Morant","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.cct.2026.108452_bb0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jclinepi.2019.05.033","article-title":"Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies","author":"Ladanie","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.cct.2026.108452_bb0045","first-page":"253","article-title":"Substantial evidence: when is a single trial sufficient for approval and promotion","author":"Coutant","year":"2010","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.cct.2026.108452_bb0050","series-title":"Demonstrating Substantial Evidence of Effectiveness with on Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence","author":"Center for Drug Evaluation and Research Center for Biologics Evaluation and Research","year":"2023"},{"key":"10.1016\/j.cct.2026.108452_bb0055","doi-asserted-by":"crossref","DOI":"10.1097\/j.pain.0000000000003287","article-title":"A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain","author":"Miller","year":"2024","journal-title":"Pain"},{"key":"10.1016\/j.cct.2026.108452_bb0060","doi-asserted-by":"crossref","DOI":"10.1097\/j.pain.0000000000002919","article-title":"Recommendations for terminology and the identification of neuropathic pain in people with spine-related leg pain. Outcomes from the NeuPSIG working group","author":"Schmid","year":"2023","journal-title":"Pain"},{"key":"10.1016\/j.cct.2026.108452_bb0065","series-title":"Statistical Methods for Research Workers","author":"Fisher","year":"1932"},{"key":"10.1016\/j.cct.2026.108452_bb0070","series-title":"Randomization Tests","author":"Edgington","year":"2007"},{"key":"10.1016\/j.cct.2026.108452_bb0075","series-title":"Statistical Methods for Research Workers","author":"Fisher","year":"1925"},{"key":"10.1016\/j.cct.2026.108452_bb0080","article-title":"The permutation testing approach: a review","author":"Pesarin","year":"2010","journal-title":"Statistica"},{"key":"10.1016\/j.cct.2026.108452_bb0085","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.pain.2003.08.001","article-title":"Core outcome domains for chronic pain clinical trials: IMMPACT recommendations","author":"Turk","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.cct.2026.108452_bb0090","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1185\/030079906X132488","article-title":"painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain","author":"Freynhagen","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.cct.2026.108452_bb0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2125.2002.01628.x","article-title":"Is intent-to-treat analysis always (ever) enough?","author":"Sheiner","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cct.2026.108452_bb0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0009-9236(95)90260-0","article-title":"Intention-to-treat analysis and the goals of clinical trials","author":"Sheiner","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cct.2026.108452_bb0105","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/art.21116","article-title":"Violation of the intent-to-treat principle and rate of missing data in superiority trials assessing structural outcomes in rheumatic diseases","author":"Baron","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cct.2026.108452_bb0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3810\/pgm.2010.07.2179","article-title":"Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain","author":"Katz","year":"2010","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.cct.2026.108452_bb0115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.semarthrit.2009.09.002","article-title":"Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis","author":"Barthel","year":"2009","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.cct.2026.108452_bb0120","first-page":"87","article-title":"Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain","author":"Vorsanger","year":"2008","journal-title":"J. Opioid Manag."},{"key":"10.1016\/j.cct.2026.108452_bb0125","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jpain.2010.03.002","article-title":"Duloxetine versus placebo in patients with chronic low back pain a 12-week, fixed-dose, randomized, double-blind trial","author":"Skljarevski","year":"2010","journal-title":"J. Pain"},{"key":"10.1016\/j.cct.2026.108452_bb0130","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","article-title":"Efficacy and safety or tapentadol extended release for the managment of chronic low back pain results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study","author":"Buynak","year":"2010","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.cct.2026.108452_bb0135","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jpainsymman.2011.04.006","article-title":"Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderat to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study","author":"Steiner","year":"2011","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.cct.2026.108452_bb0140","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1517\/14656566.2015.1060221","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain","author":"Wen","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.cct.2026.108452_bb0145","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/pme.12377","article-title":"Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study","author":"Rauck","year":"2014","journal-title":"Pain Med."},{"key":"10.1016\/j.cct.2026.108452_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00325481.2016.1128307","article-title":"Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain","author":"Rauck","year":"2016","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.cct.2026.108452_bb0155","first-page":"485","article-title":"A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy","author":"Rauck","year":"2012","journal-title":"Pain Pract."},{"key":"10.1016\/j.cct.2026.108452_bb0160","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jpain.2016.09.008","article-title":"Capsaicin 8% patch in painful diabetic peripheral neuropathy a randomized, double-blind, placebo-controlled study","author":"Simpson","year":"2017","journal-title":"J. Pain"},{"key":"10.1016\/j.cct.2026.108452_bb0165","series-title":"Permutation Tests for Complex Data: Theory, Applications, and Software","author":"Pesarin","year":"2010"},{"key":"10.1016\/j.cct.2026.108452_bb0170","series-title":"Nonparametric Statistical Methods","author":"Hollander","year":"1973"},{"key":"10.1016\/j.cct.2026.108452_bb0175","series-title":"Nonparametric Methods","year":"1984"},{"key":"10.1016\/j.cct.2026.108452_bb0180","series-title":"Modelling Longitudinal and Spatially Correlated Data","author":"Gregoire","year":"1997"},{"key":"10.1016\/j.cct.2026.108452_bb0185","series-title":"Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products","author":"Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research","year":"1998"},{"key":"10.1016\/j.cct.2026.108452_bb0190","series-title":"Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products","author":"Center for Biologics Evaluation and Research and Center for Drug Evaluation and Research","year":"2019"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426002387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426002387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:18:31Z","timestamp":1793434711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714426002387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S1551714426002387"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2026.108452","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interpreting the totality of clinical study data: is there a better way? Statistical methodology for quantitatively interpreting clinical study data across efficacy endpoints","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2026.108452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108452"}}